GLP-1 overdose and dosing errors: what FDA has reported
The short answer
A GLP-1 overdose can follow a dosing error. If you think you took too much, call Poison Help at 1-800-222-1222, which costs nothing, according to America's Poison Centers. FDA alerted the public on July 26, 2024 to errors with compounded injectable semaglutide: most reports involved patients drawing too much from a multiple-dose vial and taking five to 20 times the intended dose, and some required hospitalization.
Key takeaways
- If you think you took too much, call Poison Help at 1-800-222-1222 or use PoisonHelp.org.
- Call 911 right away for difficulty breathing, collapse, losing consciousness or a seizure.
- Units measure volume, not drug. Ask your pharmacist to confirm your dose in milligrams and milliliters.
- Don't copy a units instruction from another person, pharmacy or vial. The same units can mean different amounts of drug.
- You can report a dosing error to FDA yourself through MedWatch.
If you think you took too much, call Poison Help at 1-800-222-1222. Call 911 right away if the person is having difficulty breathing, collapses or is losing consciousness, or has a seizure.
A GLP-1 dosing error means taking a different amount of medicine from the one prescribed, almost always too much. FDA and America’s Poison Centers have both documented these errors. The pattern in their reports is clear. The errors cluster where you have to measure a dose with a syringe, and where the instructions use “units” instead of milligrams.
This page reports what those sources say, with their figures only. It can’t tell you what your dose should be. If your instructions are unclear, ask your pharmacist before you inject.
What did FDA report?
On July 26, 2024, FDA alerted health care providers, compounders and patients to dosing errors associated with compounded injectable semaglutide products. The agency had received reports of adverse events (bad health events after taking a drug), some requiring hospitalization, that may be related to overdoses from these errors.
FDA described two sources of error.
Patients measuring the wrong amount. Most reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial while giving themselves the shot. These patients took five to 20 times more than the intended dose. Most reports indicated the patients weren’t familiar with how to measure the dose using a syringe.
Prescribers calculating the wrong amount. Several reports described health care providers incorrectly calculating the intended dose when converting from milligrams to units or milliliters. Those patients took five to 10 times more than the intended dose.
FDA’s page on unapproved GLP-1 drugs adds a third category: adverse event reports that may be related to compounded semaglutide or tirzepatide prescribed in doses beyond the FDA-approved label. FDA says that could mean more product in a single dose, more frequent doses, or a faster titration schedule, meaning a faster step-up in dose.
Why do units, milliliters and milligrams get confused?
They measure different things. Milligrams (mg) measure the amount of drug. Milliliters (mL) measure the volume of liquid. “Units” are the markings on an insulin syringe, and they’re a measure of volume too.
How many milligrams sit in a given volume depends on the product’s concentration. FDA makes three points about why this goes wrong with compounded semaglutide:
- Instructions may tell users to inject in “units,” the volume of which may vary with the concentration, instead of in milligrams or milliliters.
- Concentrations vary between compounders, and a single compounder may offer multiple concentrations. The products also come in various containers, including multiple-dose vials and prefilled syringes.
- Some patients were given syringes significantly larger than the prescribed volume.
FDA gives a concrete example. In several reports, patients were told to use a U-100 (1 milliliter) insulin syringe to draw a small dose, such as 5 units (0.05 milliliter), from a multiple-dose vial. They mistakenly took 50 units instead.
The same number of units can mean different amounts of drug in different vials. So an instruction copied from another person, another pharmacy or a previous vial may not be right for the vial in your hand. Our units, mL and mg tool shows what each measurement means for your device, so you can check your instructions with your pharmacist. It doesn’t recommend a dose.
How are the approved products different?
FDA draws the contrast itself: FDA-approved injectable semaglutide products are dosed in milligrams and have standard concentrations. In that alert, FDA said they were available only in pre-filled pens.
Some approved products are drawn up with a syringe. Zepbound and Mounjaro are supplied in vials as well as pens, and their labels address the measuring problem directly. They say to use a syringe appropriate for the dose, for example a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose, and a new syringe and needle for each injection.
The labels also build in limits that relate to taking too much:
- The Zepbound KwikPen prevents you from dialing a full dose after 4 weekly doses, and the label says not to inject the leftover medicine.
- The tablet labels (Foundayo, Wegovy tablets, Rybelsus) say not to take more than one tablet per day.
Do errors happen with FDA-approved pens?
Yes. America’s Poison Centers says poison centers are most often contacted about accidental therapeutic errors with FDA-approved GLP-1 drugs. The common mistakes it names are taking doses too closely together and taking a higher than recommended dose at once. With compounded products, it says patients report accidentally taking 10 times the recommended dose because of confusing measurement units while using a syringe.
The organization reports that poison centers managed 22,966 GLP-1 agonist related exposure cases from 2019 to 2025, and gives a figure of 3,633 up to April 30, 2025. It adds a caution about its own numbers: exposures don’t necessarily represent poisonings or overdoses.
Doses taken too close together can follow a missed dose: a late dose, then the next one on the usual day. Each label has a rule for how late a missed dose can be taken. The missed dose calculator applies the label rule for your medicine to your dates.
What to do if you think you took too much
- Call Poison Help: 1-800-222-1222. You reach a live poison expert. America’s Poison Centers says its member centers provide expert advice 24/7/365 at no cost, and the service is described as fast and confidential.
- Or go online. PoisonHelp.org offers online help, and poison.org offers the webPOISONCONTROL online tool.
- Call 911 right away if the person is having difficulty breathing, collapses or is losing consciousness, or has a seizure. That’s the Poison Help site’s instruction.
Poison Help can advise on your situation.
How to lower the risk, according to FDA
FDA’s recommendations in the alerts are about communication and equipment:
- Patients are encouraged to talk with their health care provider or compounder about how to measure and give the intended dose.
- Providers and compounders are encouraged to supply the right syringe size for the intended dose and to show patients how to measure it with that syringe.
- Questions about instructions for use or the label of a compounded product go to the compounder or the telehealth platform that supplied it.
- For a multiple-dose vial, FDA says to always use a new, sterile needle and syringe for each dose, and to discard the vial within 28 days after first use even if the compounder’s instructions say longer.
FDA also states that compounded drugs are not FDA approved and should only be used in patients whose medical needs cannot be met by an FDA-approved drug. The compounded GLP-1 guide explains the rules, and the cost guide shows what the approved products cost through legitimate routes.
Reporting an error
FDA’s MedWatch program takes reports of product use errors, serious reactions and product quality problems. You can file the online form yourself. FDA’s information line is 1-888-INFO-FDA (1-888-463-6332), and pressing 2 reports into MedWatch or gets instructions.
The wider safety picture, including the boxed warning (the strongest kind the FDA requires) and counterfeit products, is in the GLP-1 safety guide.
Frequently asked questions
What should I do if I took too much semaglutide?
Call Poison Help at 1-800-222-1222 or use PoisonHelp.org. America's Poison Centers describes the service as expert advice available 24/7/365 at no cost. The Poison Help site says to call 911 right away if the person is having difficulty breathing, collapses or is losing consciousness, or has a seizure.
How many units is a dose of semaglutide?
There's no single answer, and that's the problem FDA describes. A unit is a volume marking on an insulin syringe, and FDA says the volume a unit dose represents may vary with the product's concentration, which differs between compounders. FDA-approved injectable semaglutide is dosed in milligrams. Ask your pharmacist to confirm your dose in milligrams and milliliters.
Can you overdose on an Ozempic or Wegovy pen?
Errors with approved products do happen. America's Poison Centers says poison centers are most often contacted about accidental therapeutic errors with FDA-approved GLP-1 drugs, such as taking doses too closely together or taking a higher than recommended dose at once. For any suspected overdose, call Poison Help at 1-800-222-1222.
Is 50 units of semaglutide too much?
That depends on the concentration in the vial and what was prescribed. FDA's alert describes patients who were told to take 5 units (0.05 milliliter) and mistakenly took 50 units, ten times the amount. If your instructions are in units, confirm the milligram dose with your pharmacist.
How do I report a GLP-1 dosing error to FDA?
Use MedWatch, which takes reports of product use errors as well as serious reactions and quality problems. FDA says you can fill out the online reporting form yourself. For compounded GLP-1 products, FDA also lists a fax number for the form, 1-800-FDA-0178, and its drug information office at 855-543-3784.
Sources (12)
- 1.FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
“The majority of the reports described patients mistakenly drawing up more than the prescribed dose from a multiple-dose vial during self-administration. In these instances, patients administered five to 20 times more than the intended dose of semaglutide. Most of the reports indicated that patients were unfamiliar with how to measure the intended dose using a syringe.”
- 2.FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (units and syringes)
“In several reports, patients were instructed to use a U-100 (1 milliliter) insulin syringe to draw small doses, such as a 5-unit (0.05 milliliter) dose, from a multiple-dose vial. As depicted in the figure below, these patients were directed to administer 5 units from a vial. However, these patients mistakenly administered 50 units instead.”
- 3.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
“Additionally, the agency has received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide products in doses beyond what is in the FDA-approved drug label. This could mean using more product in a single dose, taking doses more frequently or increasing the amount more quickly (titration schedule).”
- 4.America's Poison Centers - GLP-1
“Poison Centers are most often contacted about accidental therapeutic errors to FDA- approved GLP-1 drugs. Common mistakes include taking doses too closely together or taking a higher than recommended dose at once. With compounded products, patients report accidentally taking 10-times the recommended dose due to confusing measurement units while using a syringe.”
- 5.Poison Control | Call Poison Help Centers Now 1-800-222-1222
“If you think someone has been poisoned, use PoisonHelp.org or call Poison Help at 1-800-222-1222 right away.”
- 6.Reporting Serious Problems to FDA
“MedWatch is the Food and Drug Administration's (FDA) program for reporting serious reactions, product quality problems, therapeutic inequivalence/failure, and product use errors with human medical products, including drugs, biologic products, medical devices, dietary supplements, infant formula, and cosmetics.”
- 7.FDA label (DailyMed): Zepbound prescribing information, section 2.4
“Instruct patients using ZEPBOUND vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 8.FDA label (DailyMed): Mounjaro prescribing information, section 2.2
“Instruct patients using MOUNJARO vials to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL or 0.6 mL dose) and always use a new syringe and needle for each injection.”
- 9.FDA label (DailyMed): Foundayo prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 10.FDA label (DailyMed): Wegovy prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 11.FDA label (DailyMed): Rybelsus and Ozempic tablets prescribing information, section 2.1
“Do not take more than one tablet per day.”
- 12.FDA label (DailyMed): Zepbound Instructions for Use (in the prescribing information)
“After 4 doses, throw away (discard) the Pen, including the unused medicine. The Pen will prevent you from dialing a full dose after you have given yourself 4 weekly doses. Do not inject the leftover medicine.”
Related pages
- Is Ozempic safe? What the GLP-1 labels and FDA say
- Who should not take Ozempic, Zepbound or another GLP-1?
- GLP-1 drug interactions: what each label says
- Compounded semaglutide and tirzepatide: what they are and where the rules stand
- How to inject Ozempic, Zepbound and other GLP-1s: what each label says
- Dosing-error explainer
